TRX Insider Trading

Insider Ownership Percentage: 46.75%
Insider Buying (Last 12 Months): £3,657.42
Insider Selling (Last 12 Months): GBX 0

Tissue Regenix Group Insider Trading History Chart

This chart shows the insider buying and selling history at Tissue Regenix Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Tissue Regenix Group Share Price & Price History

Current Price: GBX 61
Price Change: Price Decrease of -1 (-1.61%)
As of 05/22/2024 04:46 PM ET

This chart shows the closing price history over time for TRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Tissue Regenix Group Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/15/2023Brian PhillipsInsiderBuy6,773GBX 54£3,657.42
4/4/2023Daniel LeeInsiderBuy500,000GBX 1£5,000
4/19/2022Trevor PhillipsInsiderBuy2,758,000GBX 1£27,580
12/22/2021Daniel LeeInsiderBuy1,408,450GBX 1£14,084.50
9/23/2021Brian PhillipsInsiderBuy9,000,000GBX 1£90,000
9/9/2021David CockeInsiderBuy1,086,000GBX 1£10,860
See Full Table

SEC Filings (Institutional Ownership Changes) for Tissue Regenix Group (LON:TRX)

39.47% of Tissue Regenix Group stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Tissue Regenix Group logo
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally. The company operates through dCELL, BioRinse, and GBM-V segments. It also provides dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductivity to stimulate and regenerate native bone growth. In addition, the company offers DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, a decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it provides OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company offers DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks to optimise membrane defects; and sports medicine products. Tissue Regenix Group plc was incorporated in 2006 and is based in Garforth, the United Kingdom.
Read More on Tissue Regenix Group

Today's Range

Now: GBX 61
Low: 61
High: 63

50 Day Range

MA: GBX 62.10
Low: 59.80
High: 68.75

52 Week Range

Now: GBX 61
Low: 48
High: 72.94


17,567 shs

Average Volume

59,320 shs

Market Capitalization

£43.05 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Tissue Regenix Group?

Tissue Regenix Group's top insider shareholders include:
  1. Brian Phillips (Insider)
  2. Daniel Lee (Insider)
Learn More about top insider investors at Tissue Regenix Group.